Faculty, Staff and Student Publications
Publication Date
11-14-2024
Journal
Viruses
Abstract
Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM. These engineered and non-engineered viruses infect and lyse cancer cells, causing tumor destruction without harming healthy cells. Recent advances in genetic modifications to OVs have helped improve their targeting capabilities and introduce therapeutic genes, broadening the therapeutic window and minimizing potential side effects. The efficacy of oncolytic virotherapy can be enhanced by combining it with other treatments such as immunotherapy, chemotherapy, or radiation. Recent studies suggest that manipulating the gut microbiome to enhance immune responses helps improve the therapeutic efficacy of the OVs. This narrative review intends to explore OVs and their role against solid tumors, especially GBM while emphasizing the latest technologies used to enhance and improve its therapeutic and clinical responses.
Keywords
Animals, Humans, Brain Neoplasms, Combined Modality Therapy, Gastrointestinal Microbiome, Glioblastoma, Glioma, Immunotherapy, Oncolytic Virotherapy, Oncolytic Viruses, viroimmunotherapy, therapeutic efficacy, gut microbiome, glioblastoma, combinatory therapies
DOI
10.3390/v16111775
PMID
39599889
PMCID
PMC11599061
PubMedCentral® Posted Date
11-14-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons